Stocks in News: Sun Pharma, Tata Motors, Voltas, and Tech Mahindra Lead

Indian markets snapped a five-session winning streak on Friday, ending lower as a broad-based sell-off in the IT sector weighed heavily on sentiment. While the Nifty faced resistance near the 24,150 zone, several individual stocks are making headlines due to strategic acquisitions, massive order books, and capacity expansions.

Sun Pharma and Alembic Pharma Strengthen Healthcare Portfolios

India’s largest drugmaker, Sun Pharmaceutical Industries Ltd, is set to bolster its product portfolio through a strategic acquisition. The company will acquire Mumbai-based Innovcare Lifesciences Private Ltd in an all-cash deal valued at approximately $28.7 million (around ₹271.2 crore). This move highlights Sun Pharma's aggressive stance in consolidating its market leadership.

In a similar vein of regulatory success, Alembic Pharmaceuticals Ltd announced it has received tentative approval from US health regulators for its generic version of the cancer treatment drug, Binimetinib tablets. These developments signal a robust period of growth and expansion for the Indian pharmaceutical sector on the global stage.

Tata Motors and Voltas Hit Significant Milestones

The automotive and consumer durable sectors saw major positive developments. Tata Motors has successfully secured over 3,400 orders for electric commercial vehicles (eCVs). These orders span across the freight, logistics, and passenger mobility segments, underscoring the accelerating shift toward electric mobility among Indian commercial fleet operators.

Simultaneously, Voltas, a Tata Group company, has achieved a massive scale in the cooling segment. The leading room air conditioner (RAC) maker reported selling one million units within just the first three months of the 2026-27 financial year. This record-breaking pace has further solidified Voltas's dominant position in the Indian RAC market.

Strategic Shifts at ONGC and Tech Mahindra

State-run energy giant ONGC is undergoing a significant identity shift. Chairman and CEO Arun Kumar Singh stated that the company is repositioning itself to be viewed as a "gas and oil" firm rather than an "oil and gas" company, signaling a strategic pivot toward becoming a more gas-focused energy producer.

In the technology sector, Tech Mahindra has made a significant real estate move to support its operational needs. The company has taken on a long-term lease for nearly 4 lakh sq ft of office space in Hyderabad. This transaction stands as one of the largest office leasing deals in the city this year, reflecting the sustained demand for premium workspaces by major technology occupiers.

Corporate Growth: Dalmia Bharat and Jyothy Labs

In the industrial space, Dalmia Bharat has announced plans to raise up to ₹4,000 crore through various financial instruments. This capital is earmarked for an ambitious expansion plan to increase manufacturing capacity to 110–130 million tonnes per annum by FY31 via acquisitions and new projects. Meanwhile, FMCG player Jyothy Labs is expanding its "Exo" brand into a broader dishwash franchise following the exit of Henkel AG from its licensing arrangements for Pril and Fa brands in India.

Key Takeaways

  • Pharma Expansion: Sun Pharma is investing ₹271.2 crore to acquire Innovcare Lifesciences, while Alembic Pharma gained US tentative approval for a generic cancer drug.
  • Electric & Consumer Growth: Tata Motors secured 3,400+ eCV orders, and Voltas hit a milestone of 1 million RAC units sold in just three months.
  • Energy & Infrastructure Pivot: ONGC is repositioning as a gas-centric producer, while Dalmia Bharat seeks ₹4,000 crore to fuel massive capacity expansions.